Additional Information
Book Details
Abstract
Dr. George Fedoriw leads the second issue presented in the Surgical Pathology Clinics on Hematopathology. Topics in this issue include: Evidence-based, high-value hematopathology; The expanding spectrum of follicular lymphoma; Lymphoid proliferations in the immunocompromised host; Reporting clinically relevant biomarkers of intermediate/high grade B-cell lymphomas; Transformation of lymphomas; T-cell lymphoproliferations: distinguishing benign from malignant; Lymphoma microenvironment and immunotherapy; Differentiating low grade lymphomas with non-specific immunophenotype; Molecular markers of myeloid leukemias and myelodysplastic syndromes; Update of myeloproliferative neoplasms; Mimics of myeloid neoplasms; Therapy effect: impact on bone marrow morphology. Each topic is written by a leader in pathology with expertise in hematopathology. The focus on these articles, as all in the series, is on Differential Diagnosis, with histologic images and tips for working with the most challenging aspects of these pathologies.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Hematopathology | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface\r | v | ||
| Laboratory Test Utilization Management: General Principles and Applications in Hematopathology\r | v | ||
| B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation\r | v | ||
| The Expanding Spectrum of Follicular Lymphoma\r | v | ||
| Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas\r | v | ||
| B-cell Lymphoproliferative Disorders Associated with Primary and Acquired Immunodeficiency\r | vi | ||
| Transformation in Low-grade B-cell Neoplasms\r | vi | ||
| Lymphoma Microenvironment and Immunotherapy\r | vi | ||
| Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma\r | vi | ||
| Immunoglobulin G4–Related Lymphadenopathy\r | vii | ||
| T-cell Lymphomas: Updates in Biology and Diagnosis\r | vii | ||
| Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes\r | vii | ||
| Myeloid Neoplasms with Germline Predisposition: A New Provisional Entity Within the World Health Organization Classification\r | vii | ||
| Therapy Effect: Impact on Bone Marrow Morphology\r | viii | ||
| SURGICAL PATHOLOGY CLINICS\r | ix | ||
| FORTHCOMING ISSUES | ix | ||
| June 2016 | ix | ||
| September 2016 | ix | ||
| December 2016 | ix | ||
| RECENT ISSUES | ix | ||
| December 2015 | ix | ||
| September 2015 | ix | ||
| June 2015 | ix | ||
| Preface | xi | ||
| Laboratory Test Utilization Management | 1 | ||
| ABSTRACT | 1 | ||
| OVERVIEW | 1 | ||
| TEST UTILIZATION MANAGEMENT PRINCIPLES | 2 | ||
| STRATEGY FOR TEST UTILIZATION MANAGEMENT IMPLEMENTATION | 2 | ||
| THE PRACTICE OF HEMATOPATHOLOGY AND TEST UTILIZATION | 4 | ||
| ALGORITHMIC APPROACH TO THE INITIAL WORKUP AND DIAGNOSIS OF MYELODYSPLASTIC SYNDROME | 4 | ||
| ALGORITHMIC APPROACH TO THE EVALUATION OF BONE MARROW SPECIMENS PERFORMED FOR STAGING OF LYMPHOMA | 5 | ||
| SUMMARY | 7 | ||
| ACKNOWLEDGMENTS | 7 | ||
| REFERENCES | 7 | ||
| B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation | 11 | ||
| ABSTRACT | 11 | ||
| LYMPHOPLASMACYTIC LYMPHOMA | 11 | ||
| OVERVIEW | 11 | ||
| GROSS AND MICROSCOPIC FEATURES | 12 | ||
| DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS | 12 | ||
| PROGNOSIS | 13 | ||
| EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE | 14 | ||
| OVERVIEW | 14 | ||
| GROSS AND MICROSCOPIC FEATURES | 14 | ||
| DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS | 15 | ||
| PROGNOSIS | 16 | ||
| NODAL MARGINAL ZONE LYMPHOMA | 16 | ||
| OVERVIEW | 16 | ||
| GROSS AND MICROSCOPIC FEATURES | 16 | ||
| DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS | 17 | ||
| PROGNOSIS | 18 | ||
| SPLENIC MARGINAL ZONE LYMPHOMA | 18 | ||
| OVERVIEW | 18 | ||
| GROSS AND MICROSCOPIC FEATURES | 18 | ||
| DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS | 19 | ||
| PROGNOSIS | 20 | ||
| PLASMABLASTIC LYMPHOMA | 21 | ||
| OVERVIEW | 21 | ||
| GROSS AND MICROSCOPIC FEATURES | 21 | ||
| DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS | 22 | ||
| PROGNOSIS | 24 | ||
| REFERENCES | 24 | ||
| The Expanding Spectrum of Follicular Lymphoma | 29 | ||
| ABSTRACT | 29 | ||
| OVERVIEW | 29 | ||
| FOLLICULAR LYMPHOMA VARIANTS | 30 | ||
| PEDIATRIC FOLLICULAR LYMPHOMA | 31 | ||
| ANATOMIC VARIANTS OF FOLLICULAR LYMPHOMA IN ADULTS | 34 | ||
| EARLY AND PRECURSOR LESIONS | 36 | ||
| REFERENCES | 38 | ||
| Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas | 41 | ||
| ABSTRACT | 41 | ||
| OVERVIEW | 41 | ||
| MORPHOLOGIC RISK STRATIFICATION | 43 | ||
| CELL-OF-ORIGIN DETERMINATION | 43 | ||
| MYC/BCL2/BCL6 REARRANGEMENTS AND DOUBLE-HIT LYMPHOMAS | 45 | ||
| IDENTIFICATION OF DOUBLE-HIT LYMPHOMAS | 46 | ||
| IMMUNOHISTOCHEMISTRY FOR EXPRESSION OF MYC AND BCL2 | 47 | ||
| OTHER CLINICALLY RELEVANT BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA | 47 | ||
| OTHER CLINICALLY RELEVANT BIOMARKERS IN BURKITT LYMPHOMA | 48 | ||
| NEW HORIZONS/FUTURE DIRECTIONS | 49 | ||
| REFERENCES | 49 | ||
| B-cell Lymphoproliferative Disorders Associated with Primary and Acquired Immunodeficiency | 55 | ||
| ABSTRACT | 55 | ||
| OVERVIEW | 55 | ||
| DIFFUSE LARGE B-CELL LYMPHOMA | 57 | ||
| OVERVIEW | 57 | ||
| CLINICAL FEATURES | 58 | ||
| DIAGNOSIS | 58 | ||
| PROGNOSIS | 58 | ||
| IMMUNODEFICIENCY-ASSOCIATED BURKITT LYMPHOMA | 58 | ||
| OVERVIEW | 58 | ||
| CLINICAL FEATURES | 59 | ||
| DIAGNOSIS | 59 | ||
| Transformation in Low-grade B-cell Neoplasms | 79 | ||
| ABSTRACT | 79 | ||
| OVERVIEW | 79 | ||
| BIOLOGICAL CATEGORIES OF CLINICAL TRANSFORMATION | 80 | ||
| CLINICAL FEATURES OF TRANSFORMATION | 80 | ||
| FOLLICULAR LYMPHOMA TRANSFORMATION | 81 | ||
| MECHANISMS OF TRANSFORMATION IN FOLLICULAR LYMPHOMA | 82 | ||
| MIMICS OF TRANSFORMED FOLLICULAR LYMPHOMA | 84 | ||
| RICHTER TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA | 85 | ||
| MECHANISMS OF TRANSFORMATION IN DIFFUSE LARGE B-CELL LYMPHOMA/RICHTER SYNDROME | 88 | ||
| MIMICS OF DIFFUSE LARGE B-CELL LYMPHOMA/RICHTER SYNDROME | 88 | ||
| VARIANTS OF RICHTER SYNDROME | 90 | ||
| SUMMARY | 90 | ||
| REFERENCES | 90 | ||
| Lymphoma Microenvironment and Immunotherapy | 93 | ||
| ABSTRACT | 93 | ||
| OVERVIEW | 93 | ||
| TUMOR MICROENVIRONMENT IN LYMPHOMA | 94 | ||
| SIGNALS TO AND FROM THE TUMOR MICROENVIRONMENT | 94 | ||
| EVASION FROM IMMUNE SYSTEM | 94 | ||
| CHRONIC LYMPHOCYTIC LEUKEMIA | 94 | ||
| Tumor-associated macrophages | 95 | ||
| Follicular dendritic cells | 95 | ||
| Fibroblastic reticular cells | 95 | ||
| Endothelial cells | 95 | ||
| Follicular T helper cells | 95 | ||
| Regulatory T cells | 95 | ||
| Cytotoxic T cells | 95 | ||
| Natural killer cells | 95 | ||
| Myeloid-derived suppressor cells | 95 | ||
| MICROENVIRONMENT-TARGETED IMMUNOTHERAPIES FOR CHRONIC LYMPHOCYTIC LEUKEMIA | 96 | ||
| FOLLICULAR LYMPHOMA | 97 | ||
| MICROENVIRONMENT-TARGETED IMMUNOTHERAPIES FOR FOLLICULAR LYMPHOMA | 97 | ||
| CLASSIC HODGKIN LYMPHOMA | 98 | ||
| MICROENVIRONMENT-TARGETED IMMUNOTHERAPIES FOR CLASSIC HODGKIN LYMPHOMA | 99 | ||
| SUMMARY | 99 | ||
| REFERENCES | 99 | ||
| Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma | 101 | ||
| ABSTRACT | 101 | ||
| OVERVIEW | 102 | ||
| DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN PLASMA CELL MYELOMA | 103 | ||
| NORMAL VERSUS ABNORMAL PLASMA CELLS | 103 | ||
| GENERAL TECHNICAL ISSUES RELATED TO PLASMA CELL MYELOMA FLOW CYTOMETRY | 104 | ||
| ADDED VALUE OF FLOW CYTOMETRY IN THE DIAGNOSTIC WORK-UP OF PLASMA CELL MYELOMA | 106 | ||
| PROGNOSTIC UTILITY OF FLOW CYTOMETRY IN PLASMA CELL MYELOMA | 111 | ||
| QUALITATIVE PROGNOSTIC PARAMETERS | 111 | ||
| QUANTITATIVE PROGNOSTIC PARAMETERS | 111 | ||
| MINIMAL RESIDUAL DISEASE ANALYSIS FLOW CYTOMETRY IN PLASMA CELL MYELOMA | 112 | ||
| UTILITY OF FLOW CYTOMETRY IN THERAPY-RELATED ISSUES IN PLASMA CELL MYELOMA | 113 | ||
| REFERENCES | 113 | ||
| Immunoglobulin G4–Related Lymphadenopathy | 117 | ||
| ABSTRACT | 117 | ||
| OVERVIEW | 117 | ||
| CLINICAL PRESENTATION AND GROSS FEATURES | 118 | ||
| MICROSCOPIC FEATURES | 118 | ||
| DIAGNOSIS | 121 | ||
| DIFFERENTIAL DIAGNOSIS | 122 | ||
| PROGNOSIS | 127 | ||
| REFERENCES | 128 | ||
| T-cell Lymphomas | 131 | ||
| ABSTRACT | 131 | ||
| OVERVIEW AND PRACTICAL CONSIDERATIONS | 131 | ||
| ANAPLASTIC LARGE CELL LYMPHOMA, OVERVIEW | 132 | ||
| ANAPLASTIC LARGE CELL LYMPHOMA, ANAPLASTIC LYMPHOMA KINASE POSITIVE | 132 | ||
| ANAPLASTIC LARGE CELL LYMPHOMA, ANAPLASTIC LYMPHOMA KINASE NEGATIVE | 133 | ||
| ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA | 133 | ||
| PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED | 136 | ||
| SUMMARY | 139 | ||
| REFERENCES | 139 | ||
| Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes | 143 | ||
| ABSTRACT | 143 | ||
| OVERVIEW | 143 | ||
| CYTOGENETIC TESTING IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | 144 | ||
| MOLECULAR GENETIC RISK-STRATIFICATION IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | 147 | ||
| METHODS OF DETECTING GENETIC ABERRATIONS IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | 150 | ||
| DETECTION OF TRANSLOCATIONS | 150 | ||
| DETECTION OF COPY NUMBER ABNORMALITIES | 150 | ||
| DETECTION OF POINT MUTATIONS AND INSERTION/DELETIONS | 151 | ||
| RELEVANCE OF SPECIFIC MUTATIONS IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | 151 | ||
| MYELOID TRANSCRIPTION FACTORS | 151 | ||
| CCAAT/Enhancer Binding Protein Alpha | 151 | ||
| Ets Variant 6 Gene (ETV6) | 152 | ||
| Runt-related Transcription Factor 1 (RUNX1) | 152 | ||
| SIGNAL TRANSDUCTION | 152 | ||
| FMS Like Tyrosine Kinase 3 (FLT3) | 152 | ||
| Nucleophosmin 1 (NPM1) | 154 | ||
| Tumor Protein p53 (TP53) | 155 | ||
| V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (KIT) | 155 | ||
| RNA SPLICING: SF3B1, SETBP1, SRSF, U2AF1 | 155 | ||
| COHESIN COMPLEX | 156 | ||
| EPIGENETIC MODIFIERS: GENES THAT METHYLATE DNA AND ALTER CHROMATIN STRUCTURE | 156 | ||
| DNA METHYLATION | 157 | ||
| DNA Methyl Transferase 3A (DNMT3A) | 157 | ||
| Ten-Eleven Translocation Gene-2 (TET2) | 157 | ||
| Isocitrate Dehydrogenase 1 and 2 (IDH1/IDH2) | 157 | ||
| CHROMATIN MODIFIERS | 157 | ||
| Additional Sex Combs Like Transcriptional Regulator 1 (ASXL1) | 157 | ||
| Mixed Lineage Leukemia (MLL) | 158 | ||
| Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) | 158 | ||
| REFERENCES | 158 | ||
| Myeloid Neoplasms with Germline Predisposition | 165 | ||
| ABSTRACT | 165 | ||
| OVERVIEW | 165 | ||
| SPECIAL CLINICAL FEATURES OF MYELOID NEOPLASMS ASSOCIATED WITH GERMLINE PREDISPOSITION MUTATIONS | 166 | ||
| WHAT ARE THE SPECIFIC MYELOID NEOPLASMS ASSOCIATED WITH GERMLINE PREDISPOSITION MUTATIONS? | 167 | ||
| MYELOID NEOPLASMS WITH GERMLINE PREDISPOSITION WITHOUT A PREEXISTING DISORDER OR ORGAN DYSFUNCTION | 167 | ||
| Acute Myeloid Leukemia with Germline CEBPA Mutation | 167 | ||
| Myeloid Neoplasms with Germline DDX41 Mutation | 168 | ||
| MYELOID NEOPLASMS WITH GERMLINE PREDISPOSITION AND PREEXISTING PLATELET DISORDERS | 168 | ||
| Myeloid Neoplasms with Germline RUNX1 Mutation | 168 | ||
| Myeloid Neoplasms with Germline ANKRD26 Mutation | 168 | ||
| Myeloid Neoplasms with Germline ETV6 Mutation | 169 | ||
| MYELOID NEOPLASMS WITH GERMLINE PREDISPOSITION ASSOCIATED WITH OTHER ORGAN DYSFUNCTION | 169 | ||
| Myeloid Neoplasms with Germline GATA2 Mutation | 169 | ||
| Myeloid Neoplasms with Germline\rPredisposition Associated with Inherited Bone\rMarrow Failure Syndromes and Telomere\rBiology Disorders\r | 169 | ||
| EMERGING SYNDROMES THAT LIKELY PREDISPOSE TO MYELOID MALIGNANCIES | 169 | ||
| GERMLINE ALTERATIONS AND SYNDROMES NOT DESCRIBED UNDER THE PROVISIONAL WORLD HEALTH ORGANIZATION–DEFINED CATEGORY | 170 | ||
| WHICH PATIENTS WITH MYELOID NEOPLASMS SHOULD BE TESTED FOR GERMLINE PREDISPOSITION MUTATIONS? | 172 | ||
| HOW SHOULD THE PRESENCE OF A GERMLINE PREDISPOSITION MUTATION BE ESTABLISHED? | 173 | ||
| WHAT ARE THE REMAINING CHALLENGES RELATED TO THIS NEW PROVISIONAL WORLD HEALTH ORGANIZATION CATEGORY? | 174 | ||
| SUMMARY | 174 | ||
| REFERENCES | 175 | ||
| Therapy Effect | 177 | ||
| ABSTRACT | 177 | ||
| OVERVIEW | 177 | ||
| BONE MARROW POST MYELOABLATION | 177 | ||
| FIBROSIS | 177 | ||
| NECROSIS | 178 | ||
| SEROUS ATROPHY | 178 | ||
| GROWTH FACTORS AND CYTOKINE EFFECTS | 179 | ||
| EFFECT OF SPECIFIC THERAPEUTIC AGENTS | 183 | ||
| IMATINIB | 183 | ||
| LENALIDOMIDE | 185 | ||
| RITUXIMAB | 185 | ||
| INTERFERON | 186 | ||
| REFERENCES | 186 |